News - Seattle Genetics

Filter

Current filters:

Seattle Genetics

Popular Filters

Takeda's lymphoma drug Adcetris approved in Japan

Takeda's lymphoma drug Adcetris approved in Japan

18-01-2014

Japan’s largest drugmaker Takeda Pharmaceutical has received approval from the country’s Ministry…

AdcetrisFinancialOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Seattle Genetics expands cancer drug collaboration with AbbVie

Seattle Genetics expands cancer drug collaboration with AbbVie

09-01-2014

US biotech firm Seattle Genetics says it has further expanded its antibody-drug conjugate (ADC) collaboration…

AbbVieBiotechnologyLicensingOncologySeattle Genetics

Seattle Genetics highlights Adcetris clinical data in the frontline setting

13-10-2013

US biotech firm Seattle Genetics has highlighted multiple Adcetris (brentuximab vedotin) data presentations…

AdcetrisBiotechnologyOncologyResearchSeattle Genetics

Seattle Genetics takes up option to co-develop additional ADC with Astellas

28-06-2013

Japanese drug major Astellas Pharma (TYO: 4503) says that US biotech firm Seattle Genetics (Nasdaq: SGEN)…

ASG-15MEAstellas PharmaBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

Bayer to spend up to $520 million on antibody drug conjugate deal with Seattle Genetics

26-06-2013

US biotech firm Seattle Genetics (Nasdaq: SGEN) says it has entered into a new antibody-drug conjugate…

BayerBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

Takeda files for brentuximab vedotin approval in Japan; sanctioned by JPMA

22-03-2013

Japan's largest drugmaker, Takeda Pharmaceutical (TYO: 4502) and its oncology subsidiary Millennium have…

AdcetrisAlinamin-F5Asia-PacificbrentuximabMillennium LaboratoriesOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Seattle Genetics files sBLA for Adcetris in relapsed Hodgkin lymphoma and systemic ALCL

19-03-2013

US biotech firm Seattle Genetics (Nasdaq: SGEN) has submitted a supplemental Biologics License Application…

AdcetrisBiotechnologyNorth AmericaOncologyRegulationSeattle Genetics

Regulatory news for Hyperion's Ravicti and Seattle Genetics' Adcetris

04-02-2013

The US Food and Drug Administration on Friday approved Hyperion Therapeutics' (Nasdaq: HPTX) Ravicti…

AdcetrisBiotechnologyHyperion TherapeuticsNorth AmericaOncologyPatentsPharmaceuticalRare diseasesRavictiRegulationSeattle Genetics

FDA grants Seattle Genetics' Adcetris orphan rating in MF

27-11-2012

US biotech firm Seattle Genetics (Nasdaq: SGEN) says its Adcetris (brentuximab vedotin) has been granted…

AdcetrisBiotechnologyNorth AmericaOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

European Commission grants conditional approval for Adcetris

01-11-2012

Millennium, a wholly owned subsidiary of Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502)…

AdcetrisBiotechnologyEuropeMillennium PharmaceuticalsOncologyPharmaceuticalRegulationSeattle GeneticsTakeda Pharmaceuticals

Seattle Genetics and Abbott expand ADC collaboration

24-10-2012

Seattle Genetics and Abbott expand ADC collaboration

Abbott LaboratoriesBiotechnologyLicensingOncologyPharmaceuticalSeattle Genetics

“Black box” warning for Seattle Genetics’ Adcetris

16-01-2012

US biotech Seattle Genetics (Nasdaq: SGEN) saw its shares fall 5.2% to $17.49 on Friday, after the company…

AdcetrisBiotechnologyNorth AmericaOncologyRegulationSeattle Genetics

Back to top